CTNM Earnings Date: Mar 4, 2027 (Estimated) — Contineum Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CTNM's next earnings date?
Contineum Therapeutics, Inc. (CTNM) is expected to report Q4 2026 earnings on Thursday, March 4, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.45 on revenue of $5.0M.
How did CTNM do in its last earnings report?
In its most recent report on Jul 30, 2026 (Q2 2026), Contineum Therapeutics, Inc. posted EPS of -$0.40 versus the -$0.45 estimate, a beat of 11.1%. Revenue was $0. The stock's 1-day post-earnings move was -1.7%.
How much does CTNM stock move after earnings?
CTNM beat EPS estimates in 3 of its last 7 reported quarters. Over the last 7 reports the stock moved an average of 3.6% (up or down) in the day after earnings.
About Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
🤖 AI Earnings Analysis
CTNM’s depression-drug failure and 9.9% analyst-driven drop outweigh its Buy upgrade; negative P/E of -4.8 underscores ongoing losses and elevated execution risk.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | Q2 2026 | -0.45 | -0.40 | +11.11% | $0 | ✅ Beat | -1.65% | -2.54% | +8.25% |
| 2026-05-05 | Q1 2026 | -0.54 | -0.39 | +27.78% | $0 | ✅ Beat | +1.70% | -3.53% | -11.80% |
| 2026-03-05 | Q4 2025 | -0.43 | -0.49 | -13.95% | $0 | ❌ Miss | +0.51% | +0.36% | -2.68% |
| 2025-10-30 | Q3 2025 | -0.51 | -0.45 | +11.76% | $0 | ✅ Beat | +4.46% | +4.46% | +4.27% |
| 2025-08-05 | Q2 2025 | -0.47 | -0.62 | -31.91% | $0 | ❌ Miss | +5.50% | +12.50% | +83.17% |
| 2025-03-06 | Q4 2024 | -0.44 | -0.56 | -27.27% | $0 | ❌ Miss | +5.12% | +10.87% | -9.94% |
| 2024-08-13 | Q2 2024 | -0.35 | -0.39 | -11.43% | $0 | ❌ Miss | +6.21% | +8.17% | +10.94% |
| 2024-05-16 | Q1 2024 | — | -3.55 | — | $0 | — | — | — | — |
Showing last 8 quarters.